Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer

Innovation Pharmaceuticals (OTCQB:IPIX) a clinical stage biopharmaceutical company, today announces the closure of its Phase 2a clinical trial of Kevetrin for the treatment of late-stage Ovarian Cancer. The Company initiated the trial for the purpose of demonstrating modulation of the key tumor-suppressor protein p53, which was achieved in analysis of the first patients at the lowest dose of Kevetrin.

As quoted in the press release:

“This study delivered multiple insights into how Kevetrin modulates the p53 protein and affects related molecular pathways,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Moreover, if we successfully transition to oral dosing of Kevetrin, we believe the therapeutic effect will be maximized, providing important benefits to cancer patients in need—beyond the ultimate convenience of oral delivery. An effective orally-delivered p53-modulating drug has the potential to transform cancer care and we are proud to be at the forefront toward achieving this goal.”

Click here to read the full press release.